Skip to content

Challenging Science. Changing Lives.

Amylin Pharmaceuticals is an exceptional company of extraordinary people. Their willingness to challenge conventional thinking as much as they challenge themselves, their resolve, resiliency and passion for the patient are improving the lives of millions.

The men and women of Amylin are discovering, developing, and bringing to market innovative therapies with life-changing potential for people struggling with diabetes and obesity—merging epidemics that are fast becoming the major health crises of our lifetime. In the process, they are building an exciting new franchise in the treatment of metabolic disease and a pipeline of possibilities for future healthcare solutions.

Building Blocks

The two building blocks upon which Amylin was founded-Challenging Science and Changing Lives-remain the cornerstone of our mission today. We hope this blog will serve as an additional means to convey our passion for protein and peptide science, and the potential of harnessing these molecular "building blocks" to treat metabolic diseases, and further our dedication to improving patients' lives.

To learn more, visit the Building Blocks website.

Recent Blog Posts

  • Jan05

    “If You Bought It, A Truck Brought It.” Why We Should Care About Diabetes’ Impact on the Trucking Industry

    Receiving a diagnosis of type 2 diabetes and learning how to manage the disease can be difficult for anyone. But for people with safety-sensitive jobs, such as commercial vehicle (CMV) drivers, a diagnosis of diabetes could potentially be career-ending. The Read More

  • Nov18

    Highlights from EASD 2011

    Every year in September, thousands of scientists, endocrinologists and diabetes educators from all over the world gather for the annual meeting of the European Association of the Study of Diabetes (EASD). The venue chosen for this year’s meeting was Lisbon, Read More

Spotlight

Amylin is committed to maximizing the value of exenatide for patients and physicians across the globe.

Click here to read more.

News & Events

  • Jan 30

    Amylin Pharmaceuticals to Webcast 2011 Year-End Financial Results Full Story

  • Jan 27

    FDA Approves BYDUREON™ -- The First and Only Once-Weekly ... Full Story

  • Jan 9

    Amylin Outlines Corporate Strategy to Maximize Global Value of Diabete... Full Story

View All

  • Jan 27

    Amylin Pharmaceuticals, Inc. Corporate Update Full Story

  • Jan 09

    Amylin Pharmaceuticals, Inc. at JPMorgan Global Healthcare Conference Full Story

  • Nov 10

    Amylin Pharmaceuticals Inc at Credit Suisse Group Healthcare Conferenc... Full Story

View All

Patients

Investors

Patient Stories Amylin has an ambitious and challenging goal: to change the lives of millions of people living with diabetes. To make that happen, they’ve delivered two first-in-class medicines.
Thumb: Investors Our Investor Relations Center is provided to give you convenient access to company information, including financial reports, press releases and corporate events. You can also sign up to be reminded via email.